Breaking News

Cambrian Bio Launches Amplifier Therapeutics

Amplifier will develop the clinical stage pan-AMPK activator, ATX-304.

Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, launched its new pipeline company, Amplifier Therapeutics. The organization will develop ATX-304, a pan-AMPK (AMP-activated protein kinase) activator. In addition, Amplifier has acquired Betagenon AB, a Swedish biopharmaceutical company, which has discovered novel AMPK activators and will continue development as a part of the Amplifier team. According to the company, AMPK i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters